The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer

Hope S. Rugo, MD
Published Online:6:01 PM, Tue May 30, 2017

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.